Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 ReadoutSeeking Alpha • 02/09/21
Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock?Zacks Investment Research • 01/15/21
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company UpdateBusiness Wire • 01/11/21
Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare ConferenceBusiness Wire • 12/23/20
Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed GlioblastomaBusiness Wire • 12/14/20
First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed GlioblastomaBusiness Wire • 12/10/20
IBD Stock Of The Day Breaks Out To A Record High As 2021 Catalysts LoomInvestors Business Daily • 12/04/20
AMD, Twilio, Novocure Among 5 Stocks Flashing Multiple Buy SignalsInvestors Business Daily • 11/21/20
Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual MeetingBusiness Wire • 11/19/20
Novocure Announces Closing of $150 Million Revolving Credit Facility with a Syndicate of Relationship BanksBusiness Wire • 11/09/20
Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private PlacementBusiness Wire • 11/05/20
Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior NotesBusiness Wire • 11/02/20
Novocure Ltd (NVCR) CEO Asaf Danziger on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/29/20
Novocure Reports Third Quarter 2020 Financial Results and Provides Company UpdateBusiness Wire • 10/29/20
Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical ResearchBusiness Wire • 10/29/20